Healthcare Industry News: Bristol-Myers Squibb
News Release - May 27, 2008
Cantel Medical Appoints New DirectorLITTLE FALLS, N.J.--(HSMN NewsFeed)--CANTEL MEDICAL CORP. (NYSE:CMN ) announced the appointment of George L. Fotiades to fill the vacancy created by the resignation of R. Scott Jones as a director on April 23, 2008. Mr. Fotiades is Chairman of the healthcare investment practice of Diamond Castle Holdings LLC, a private equity investment firm. Prior to joining Diamond Castle in 2007, Mr. Fotiades was President and Chief Operating Officer of Cardinal Health, Inc., a leading provider of products and services supporting the healthcare industry. Prior to that position, he served as President and CEO of Cardinal's Pharmaceutical Technologies and Services segment, the largest provider of contract manufacturing and packaging services to the pharmaceutical industry. Previously, he served in a variety of executive roles including President of Warner-Lambert's consumer healthcare business and senior positions at Bristol-Myers Squibb, Wyeth and Procter & Gamble.
Mr. Fotiades is non-executive Chairman of Catalent Pharma Solutions and a Director of ProLogis (NYSE:PLD ) and The Alberto-Culver Company (NYSE:ACV ). He holds an A.B. from Amherst College and an M.M. from the Kellogg School of Management at Northwestern University.
Charles M. Diker, Cantel’s Chairman, commented, “George’s experience in the healthcare industry – both in operations and finance – make him a valuable addition to the Board.”
Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
Source: Cantel Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.